Recent advances in proteomics have revealed remarkable convergence in protein alterations across distinct neurodegenerative diseases. While Alzheimer's disease (AD), Parkinson's disease (PD), and frontotemporal dementia (FTD) have traditionally been studied as separate entities, large-scale proteomic analyses demonstrate shared molecular signatures that transcend disease-specific classifications. These transdiagnostic patterns center particularly on immune-related pathways, with APOE ε4 carriers showing common proteomic signatures across multiple neurodegenerative conditions [1][2].
The recognition of transdiagnostic proteomic changes has profound implications for understanding disease mechanisms, developing biomarkers, and identifying therapeutic targets that may benefit multiple neurodegenerative conditions simultaneously.
¶ The APOE Gene and Protein
APOE encodes apolipoprotein E, a lipid transport protein with critical roles in brain homeostasis. The three common alleles (ε2, ε3, ε4) encode proteins with differential effects on lipid metabolism, amyloid clearance, and neuroinflammation. The ε4 allele is the strongest genetic risk factor for late-onset AD and modifies risk in other neurodegenerative diseases.
APOE ε4 carriers demonstrate distinctive proteomic profiles:
- Increased amyloid-related proteins: Elevated Aβ1-40, Aβ1-42 in cerebrospinal fluid (CSF)
- Lipid metabolism alterations: Changes in apolipoproteins and lipid transport proteins
- Synaptic protein reductions: Decreased synaptophysin, PSD95
- Inflammatory marker elevations: Increased IL-6, TNF-α, C-reactive protein
- Tau pathology acceleration: Higher CSF tau and p-tau levels
APOE ε4 carriers with PD show:
- Accelerated cognitive decline: More rapid progression to dementia
- Enhanced α-synuclein pathology: Increased Lewy body burden
- Alterations in lipid metabolism: Similar to AD patterns
- Immune activation signatures: Elevated microglial markers
- White matter integrity reduction: Enhanced white matter lesion load
APOE ε4 modifies FTD phenotypes:
- Earlier onset: Carriers develop symptoms earlier
- Increased amyloid co-pathology: Higher rates of amyloid co-occurrence
- Immune pathway activation: Similar inflammatory signatures to AD
- TDP-43 pathology modification: Potential interactions with proteostasis pathways
The following immune-related proteins show altered levels across multiple neurodegenerative diseases:
graph TD
subgraph "Shared Immune Proteins"
A["IL6"] --> B["TNF-alpha"]
A --> C["IL1-beta"]
C --> D["CRP"]
B --> E["Complement C3"]
D --> F["C4b"]
E --> G["TREM2"]
F --> H["ApoE"]
G --> H
end
subgraph "Disease Context"
I["AD"] --> A
J["PD"] --> A
K["FTD"] --> A
L["ALS"] --> A
end
Key shared immune proteins:
| Protein |
AD Change |
PD Change |
FTD Change |
| IL-6 |
↑ |
↑ |
↑ |
| TNF-α |
↑ |
↑ |
↑ |
| C3 |
↑ |
↑ |
↑ |
| TREM2 |
↑ (variants) |
↑ |
↑ |
| APOE |
ε4: ↑ |
ε4: ↑ |
ε4: ↑ |
Proteostasis machinery shows transdiagnostic alterations:
- Ubiquitin system: Increased ubiquitinated proteins across all diseases
- ** autophagy proteins**: Altered LC3, p62, LAMP levels
- ER stress markers: Elevated CHOP, BiP/GRP78
- Heat shock proteins: Variable changes in HSP70, HSP90
Synaptic dysfunction represents a common endpoint:
- Synaptophysin: Reduced in AD, PD, FTD
- PSD-95: Decreased across diseases
- SNAP-25: Altered in multiple conditions
- Synaptotagmin: Variable changes
- Neurogranin: Reduced in AD and PD
Energy metabolism defects are shared:
- Complex I subunits: Reduced in PD, also altered in AD
- ATP synthase: Decreased across diseases
- Mitochondrial DNA proteins: Altered in multiple conditions
- Sirtuins (SIRT1-3): Generally reduced
While shared signatures exist, disease-specific patterns remain:
- Aβ peptides: Aβ1-40, Aβ1-42 elevation
- Tau proteins: Total tau, phosphorylated tau (p-tau181, p-tau217)
- APP processing proteins: BACE1, presenilins
- Synaptic plasticity proteins: Arc, NMDA receptor subunits
- α-Synuclein: Total and phosphorylated forms
- DJ-1: Park7 mutations/alterations
- PINK1: Mitophagy markers
- L RRK2: Kinase activity markers
- TDP-43: Proteolytic fragments
- FUS: Nuclear/cytoplasmic ratio
- Tau: 4R-tau isoforms
- GRN: Progranulin levels
Shared proteomic signatures offer opportunities for:
- Cross-diagnostic biomarkers: IL-6, TNF-α, APOE as general neurodegeneration markers
- Disease progression markers: Shared synaptic protein reductions
- Therapeutic response indicators: Immune pathway normalization
Key shared pathways for drug development:
- TREM2-ApoE axis: Modulating microglial activation
- Inflammatory cytokines: IL-6, TNF-α targeting
- Proteostasis enhancement: Improving protein clearance
- Synaptic protection: Preventing synaptic protein loss
Transdiagnostic proteomic understanding enables:
- Basket trials: Including multiple diagnoses based on biomarker profiles
- Patient stratification: Using proteomic signatures for enrichment
- Outcome measures: Shared endpoints across diseases
Large consortia are characterizing transdiagnostic patterns:
- Banner Sun Health Research Institute: Brain banks with multiple diagnoses
- Accelerating Medicines Partnership: AD (AMP-AD): Multi-omics integration
- International Parkinson's Disease Genomics Consortium (IPDGC): PD proteomics
- Frontotemporal Dementia Prevention Initiative: FTD biomarkers
- Single-cell proteomics: Cell-type specific signatures
- Spatial proteomics: Regional vulnerability patterns
- Phosphoproteomics: Signaling pathway alterations
- Glycoproteomics: Post-translational modification changes
Transdiagnostic proteomic analysis reveals that neurodegenerative diseases share fundamental molecular mechanisms, particularly in immune activation and proteostasis. APOE ε4 carriers demonstrate common proteomic signatures across AD, PD, and FTD, highlighting a shared genetic modifier of neurodegeneration. These findings challenge traditional disease boundaries and open new avenues for cross-diagnostic biomarkers and therapies.